The purpose of this study is to test the good and bad effects of the drug called durvalumab in combination with the chemotherapy drugs gemcitabine and cisplatin. We are doing this study because we want to find out if this approach is better or worse than the usual approach for liver cancer.

The combination of gemcitabine, cisplatin, and durvalumab has been approved by the U.S. Food and Drug Administration (FDA) as front line therapy for advanced biliary tract cancers, including intrahepatic cholangiocarcinoma.

All study participants will receive durvalumab, gemcitabine, and cisplatin for up to 12 weeks. After the first 6 weeks of treatment, participants will undergo restaging with imaging and a doctor’s visit to make sure that it is reasonable to continue with the second half of the preoperative treatment.

After completing the 12 weeks of treatment, participants will be evaluated to make sure they are fit to go to surgery. After recovering from the operation, the doctors will determine whether participants are able to receive the study drugs after surgery for up to 12 more weeks.